GSK Pharma Q2 results: profit up, revenue dips; Rs 1.74 cr solar investment
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than Nifty Midcap 150 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone Q2 revenue fell to Rs 973.6 cr from about Rs 1,000 cr YoY. Net profit rose to Rs 255 cr from Rs 248.7 cr, aided by Rs 2.6 cr exceptional gain from sale of surplus residential properties. EBITDA margins compressed. H1 consolidated PAT at Rs 462.5 cr vs Rs 434.8 cr. Board approved Rs 1.74 cr investment in a solar power SPV for the Nashik plant. Deloitte Haskins and Sells LLP issued an unmodified limited review.
Soft revenue with margin pressure, but profit supported by one-time gains. Small solar capex is a positive ESG step. Overall results are largely flat.